title: Initial, long-term, and durable responses to terazosin, placebo, or other therapies for chronic prostatitis/chronic pelvic pain syndrome.
abstract: OBJECTIVE
  To evaluate the initial, long-term, and durable response rates to terazosin, placebo, or other therapies in patients with chronic prostatitis/chronic pelvic pain syndrome.
  
  
  METHODS
  A total of 100 subjects, aged 20 to 50 years, who met the National Institutes of Health criteria for chronic prostatitis/chronic pelvic pain syndrome and had not previously been treated with alpha-blockers, were entered in a 14-week, double-blind comparison of terazosin or placebo therapy. Nonresponders and responders with subsequent relapse were treated with terazosin or other medications (open label). The criterion for response was a score of 0 to 2 on the National Institutes of Health Chronic Prostatitis Symptom Index quality-of-life item. The initial response was evaluated at week 14, and the long-term response was evaluated after a median of 38 weeks (range 34 to 42), regardless of any additional treatment. A durable response was defined as an initial response without additional treatment.
  
  
  RESULTS
  Of the 43 patients in the terazosin group, 24 (56%) had an initial response compared with 14 (33%) of 43 subjects in the placebo group (P = 0.03). Long-term responses were noted in 23 (56%) of 41 assessable subjects treated with terazosin initially compared with 12 (32%) of 38 assessable subjects treated with placebo (P = 0.03). Of the nonresponders and initial responders with relapse, 7 (41%) of 17 subjects responded to terazosin compared with 7 (21%) of 34 given other treatment (P = 0.12). Durable responses occurred in 18 (44%) of the 41 assessable patients treated initially with terazosin and in 6 (16%) of 38 treated initially with placebo (P = 0.01).
  
  
  CONCLUSIONS
  Patients treated with terazosin were more likely to have initial, long-term, and durable responses than those treated with placebo.
authors.affiliation: University of Science Malaysia School of Pharmaceutical Sciences, Penang, Malaysia.
authors.forename: Phaik Yeong
authors.initials: PY
authors.lastname: Cheah
authors.forename: Men Long
authors.initials: ML
authors.lastname: Liong
authors.forename: Kah Hay
authors.initials: KH
authors.lastname: Yuen
authors.forename: Chu Leong
authors.initials: CL
authors.lastname: Teh
authors.forename: Timothy
authors.initials: T
authors.lastname: Khor
authors.forename: Jin Rong
authors.initials: JR
authors.lastname: Yang
authors.forename: Hin Wai
authors.initials: HW
authors.lastname: Yap
authors.forename: John N
authors.initials: JN
authors.lastname: Krieger
mesh_terms: D000317:Adrenergic alpha-Antagonists / Q000627:therapeutic use*; D000328:Adult; D002908:Chronic Disease; D004311:Double-Blind Method; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D017699:Pelvic Pain / Q000188:drug therapy*; D011224:Prazosin / Q000031:analogs & derivatives* / Q000627:therapeutic use; D011472:Prostatitis / Q000188:drug therapy*; D011788:Quality of Life; D012107:Research Design; D013577:Syndrome; D013997:Time Factors
chemical_list: D000317:Adrenergic alpha-Antagonists; C041226:Terazosin; D011224:Prazosin